The male infertility market is expected to grow to $301.5 million by 2020 with a CAGR of 5% during 2014-2020. Male infertility is defined as the inability of a male to impregnate his female partner after a year of unprotected intercourse. 20% of the total infertility is due to male factors. The major factors driving the male infertility market are the change in lifestyle, increasing age, environmental effects, etc., and these factors are majorly contributing to the rise in male infertility levels. The major limitation experienced in the male infertility market is due to repeated treatment failures leading to an emotional impact on the patient. Research Beam Model: Research Beam Product ID: 13704 5370 USD New
Male Infertility Market (Techniques and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2012 - 2020
 
 

Global Male Infertility Market (Techniques and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2012 - 2020

  • Category : Medical Devices
  • Published On : April   2014
  • Pages : 80
  • Publisher : Allied Market Research
 
 
 

The male infertility market is expected to grow to $301.5 million by 2020 with a CAGR of 5% during 2014-2020. Male infertility is defined as the inability of a male to impregnate his female partner after a year of unprotected intercourse. 20% of the total infertility is due to male factors. The major factors driving the male infertility market are the change in lifestyle, increasing age, environmental effects, etc., and these factors are majorly contributing to the rise in male infertility levels.

The major limitation experienced in the male infertility market is due to repeated treatment failures leading to an emotional impact on the patient. The repeated failures would compel most patients to discontinue the treatment. The other limitation is the social taboo. Out of 32-40% infertile men, only 15% of the men opt for the treatment for infertility due to the embarrassment, guilt, etc.

The opportunity driving the market is medical tourism and increase in awareness about male infertility. The treatment for male infertility is expensive; however, the cost of the treatment is expected to decrease with the advancement in treatment technologies. The other factor that may drag the prices lower would be the patients’ expectations for cost effective treatments. These factors would drive the male infertility market.

Male Infertility Semen Analysis Techniques Market Analysis

The male infertility techniques market is segmented into DNA fragmentation technique, oxidative stress analysis, microscopic examination, sperm penetration assay, sperm agglutination, computer assisted semen analysis and others. The DNA fragmentation is an emerging technique; it is currently being used as a routine technique in the developed nations. However, it is yet to come into routine analysis in the labs of the developing nations, as cost being the major hindrance in their usage.

Male Infertility Geographic Market Analysis

The male infertility market is segmented into North America, Europe, Asia Pacific and RoW. The North American market is the dominating market with the highest revenue, followed by the Asia pacific market. The Asia pacific market and RoW region are expected to have the highest potential for growth in the analysis period. This is due to the adoption of the new techniques in the treatment of male infertility, such as DNA fragmentation and computer assisted semen analysis. The growth in these regions can also be accredited to the rising infertility levels and awareness about infertility and its treatments.

Competitive Landscape

The companies profiled in this report are ASKA Pharmaceutical Co. Ltd, ZydusCadila Healthcare Limited, Access Pharmaceuticals, Inc., Intas Pharmaceuticals Ltd., Pantarhei Bioscience B, Cordex Pharma, Inc., Merck Serono, Halotech DNA SL, SCSA diagnostics, Andrology Solutions.

High Level Analysis

The report analyzes various techniques used in the treatment of male infertility problems. The microscopic examination segment occupied the highest share in the male infertility techniques market in 2012. This is due to its routine use in the diagnosing of male infertility problems, as it is a basic test. DNA fragmentation segment is expected to have the highest market share by 2020, due to its accurate test results that help physicians to diagnose exact issues and suggest appropriate treatments that lead couples to conceive. 

KEY BENEFITS

  • The report provides detailed analysis about the driving and limiting factors of the male infertility market, which would give a deeper understanding of the subject and help in taking actionable decisions. 
  • The market size of the male infertility diagnostic and treatments will help in analyzing the market, thus helping the stakeholders understand opportunities  in the male infertility market 
  • Market share analysis of both male and female infertility treatments that allow the decision makers to gauge the market strength and make profitable investments 
  • The report analyzes the market condition in a comprehensive and quantitative manner and forecast market trends and techniques used in male infertility treatments 

Reason for the Study

  • To study the various techniques used to treat male infertility 
  • To identify the benefits of the new techniques over the conventional techniques 
  • To study the treatment trends in various geographic regions

KEY DELIVERABLES
The global male infertility market is segmented based on techniques and geography.

MARKET BY TECHNIQUES

  • DNA Fragmentation Technique
  • Oxidative Stress Analysis
  • Microscopic Examination
  • Sperm Penetration Assay
  • Sperm Agglutination
  • Computer Assisted Semen Analysis 
  • Others

MARKET BY GEOGRAPHY

  • North America
  • Europe
  • Asia Pacific
  • RoW

CHAPTER 1 INTRODUCTION
 1.1 Key deliverables
 1.2 Research Methodology
    1.2.1 Secondary research
    1.2.2 Primary research
    1.2.3 Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY
CHAPTER 3 MARKET SIZING

 3.1 Market definition
    3.1.1 Basics of infertility treatment techniques
      3.1.1.1 Surgery
        3.1.1.1.1 VARICOCELECTOMY
        3.1.1.1.2 OTHER SURGICAL METHODS
      3.1.1.2 Treatment for problems in intercourse.
        3.1.1.2.1 ERECTILE DYSFUNCTION
        3.1.1.2.2 PREMATURE EJACULATION
      3.1.1.3 Hormone treatment
        3.1.1.3.1 HORMONAL AGENTS
        3.1.1.3.2 NON-HORMONAL AGENTS
      3.1.1.4 ART technology
        3.1.1.4.1 TESTICULAR FINE NEEDLE ASPIRATION
        3.1.1.4.2 MICROSURGICAL EPIDIDYMAL SPERM ASPIRATION
        3.1.1.4.3 TESTICULAR SPERM EXTRACTION
        3.1.1.4.4 TESTICULAR SPERM ASPIRATION
      3.1.1.5 Treatment for Retrograde Ejaculation and Failure of Emission
      3.1.1.6 Vasectomy Reversal (Vasovasostomy)
      3.1.1.7 Reversal vasectomy versus ART
 3.2 Male infertility market drivers
    3.2.1 Life style issues
    3.2.2 Environmental factors
    3.2.3 Advancement in technology
    3.2.4 Physical causes
    3.2.5 Rise in infertility rates
    3.2.6 Age
 3.3 Male infertility market restraints
    3.3.1 Impact of repeated failures in treatments
    3.3.2 Social taboos
 3.4 Challenges and opportunities
    3.4.1 Medical tourism
    3.4.2 Increased awareness level may lead to market growth
 3.5 Demand analysis
    3.5.1 Level of infertility couples (males versus female)
    3.5.2 Number of couple who opt for infertility diagnostics
    3.5.3 Total population under IVF treatment
    3.5.4 Success rate for IVF treatment
 3.6 Male versus Female infertility treatment market
 3.7 Market size for male infertility diagnostics market
    3.7.1 Global male infertility market by techniques
    3.7.2 Global male infertility techniques market by geography
    3.7.3 Market size for male infertility treatments market

CHAPTER 4 CONSIDERATIONS AND PROCESS – MALE INFERTILITY & IVF TREATMENT
 4.1 Causes of male infertility
 4.2 Evaluation of male infertility
 4.3 Semen Analysis
    4.3.1 Lab testing
    4.3.2 Blood tests
    4.3.3 Genetic tests
    4.3.4 Other tests
 4.4 Treatments of male infertility
    4.4.1 Reproductive tract blockage
    4.4.2 Gonadotropin treatment
    4.4.3 Varicocele
    4.4.4 Others
 4.5 ART for male infertility
    4.5.1 IVF
    4.5.2 ICSI
    4.5.3 TESE (testicular extraction of sperm)
    4.5.4 Limitation of ART
    4.5.5 Emotional support during infertility treatment

CHAPTER 5 SEMEN ANALYSIS TECHNIQUES – MARKET SIZE AND ANALYSIS
 5.1 DNA fragmentation
    5.1.1 Introduction
    5.1.2 When and why is DNA fragmentation conducted
    5.1.3 Consistency and accuracy of data generated from the tests and importance in deciding the ART treatments
    5.1.4 Available tests for sperm DNA fragmentation
      5.1.4.1 SCSA (Sperm chromatin structure assay)
      5.1.4.2 TUNEL assay
      5.1.4.3 Halo test
      5.1.4.4 Comet assay
      5.1.4.5 Unexplained infertility treatment
    5.1.5 DNA testing benefits
    5.1.6 Sperm DNA damage and reproductive outcomes
    5.1.7 Limitations
    5.1.8 Global male infertility DNA fragmentation market by geography, 2012-2020 ($Million)
 5.2 Oxidative stress analysis
    5.2.1 ROS induced DNA damage and apoptosis
    5.2.2 Reasons for oxidative stress
    5.2.3 Lifestyle changes
      5.2.3.1 Consumption of alcohol
      5.2.3.2 Smoking
      5.2.3.3 Psychological stress
    5.2.4 Aging
    5.2.5 Infection – MAGI (Male accessory sex gland infection)
    5.2.6 Environmental Factors
      5.2.6.1 Electromagnetic radiation
      5.2.6.2 Toxins and chemicals
      5.2.6.3 Iatrogenic
      5.2.6.4 Chemotherapy and Drugs
      5.2.6.5 Varicocele
    5.2.7 When and why oxidative stress analysis test is conducted
    5.2.8 Consistency and accuracy of data generated from the tests and importance in deciding the ART treatments
    5.2.9 Available tests for Oxidative stress analysis
      5.2.9.1 Chemiluminescence
      5.2.9.2 Lipid peroxidation markers
      5.2.9.3 Measurement of oxidative DNA damage
      5.2.9.4 Other methods of ROS measurement
    5.2.10 Global male infertility oxidative stress market by geography, 2012-2020 ($Million)
 5.3 Sperm penetration assay
    5.3.1 Consistency and accuracy of data generated from the tests and importance in deciding the ART treatments
      5.3.1.1 The reasons for the tests
      5.3.1.2 Sperm Penetration Tests
      5.3.1.3 Sperm Mucus Penetration Test
      5.3.1.4 Sperm Penetration Assay
    5.3.2 Global male infertility sperm penetration assay market by geography, 2012-2020 ($Million)
 5.4 Computer assisted semen analysis
    5.4.1 Consistency and accuracy of data generated from the tests and importance in deciding the ART treatments
    5.4.2 Functions of computer assisted sperm analysis
    5.4.3 Global male infertility CASA market by geography, 2012-2020 ($Million)
 5.5 Sperm Agglutination
    5.5.1 Consistency and accuracy of data generated from the tests and importance in deciding the ART treatments
      5.5.1.1 MAR test
      5.5.1.2 Immunobead Binding
      5.5.1.3 Diagnosis
    5.5.2 Global male infertility sperm agglutination market by geography, 2012-2020 ($Million)
 5.6 Microscopic examination
    5.6.1 Consistency and accuracy of data generated from the tests and importance in deciding the ART treatments
      5.6.1.1 Sperm concentration
    5.6.2 Global male infertility microscopic examination market by geography, 2012-2020 ($Million)
 5.7 Others
    5.7.1 Consistency and accuracy of data generated from the tests and importance in deciding the ART treatments
    5.7.2 Global male infertility others market by geography, 2012-2020 ($Million)

CHAPTER 6 GLOBAL MALE INFERTILITY MARKET BY GEOGRAPHY
 6.1 North America
    6.1.1 North American male infertility market, 2012-2020
 6.2 Europe
    6.2.1 Europe male infertility market, 2012-2020
 6.3 Asia pacific
    6.3.1 Asia pacific male infertility market, 2012-2020
 6.4 RoW
    6.4.1 RoW male infertility market, 2012-2020

CHAPTER 7 COMPANY PROFILES
 7.1 EMD Serono, Inc.
    7.1.1 Company overview
    7.1.2 Company snapshot
    7.1.3 Business performance
 7.2 Cadila Healthcare Ltd.(ZydusCadila group)
    7.2.1 Company overview
    7.2.2 Company snapshot
 7.3 ASKA pharmaceuticals, Inc.
    7.3.1 Company overview
    7.3.2 Company snapshot
    7.3.3 Business performance
    7.3.4 Strategic moves and developments
 7.4 Intas pharmaceuticals Ltd.
    7.4.1 Company overview
    7.4.2 Company snapshot
    7.4.3 Business performance
 7.5 Pantarhei Bioscience B.V.
    7.5.1 Company overview
    7.5.2 Company snapshot
 7.6 Cordex Pharma, Inc.
    7.6.1 Company overview
    7.6.2 Company snapshot
 7.7 Halotech DNA SL
    7.7.1 Company overview
    7.7.2 Company snapshot 
    7.7.3 Financial Performance
 7.8 SCSA diagnostics, Inc.
    7.8.1 Company overview
    7.8.2 Company snapshot
    7.8.3 Financial Performance
 7.9 Andrology solutions
    7.9.1 Company overview
    7.9.2 Company snapshot
 7.10 Access Pharmaceuticals, Inc.
     7.10.1 Company overview
     7.10.2 Company snapshot
     7.10.3 Business performance

LIST OF TABLES
TABLE 1 GLOBAL MALE INFERTILITY TECHNIQUES MARKET BY GEOGRAPHY, 2012-2020 ($MILLION)
TABLE 2 GLOBAL MALE INFERTILITY MARKET BY TECHNIQUES,2012-2020 ($MILLION)
TABLE 3 GLOBAL MALE INFERTILITY TECHNIQUES MARKET BY GEOGRAPHY, 2012-2020 ($MILLION)
TABLE 4 GLOBAL MALE INFERTILITY DNA FRAGMENTATION MARKET BY GEOGRAPHY, 2012-2020 ($MILLION)
TABLE 5 GLOBAL MALE INFERTILITY OXIDATIVE STRESS MARKET BY GEOGRAPHY, 2012-2020 ($MILLION)
TABLE 6 GLOBAL MALE INFERTILITY SPERM PENETRATION ASSAY MARKET BY GEOGRAPHY, 2012-2020 ($MILLION)
TABLE 7 GLOBAL MALE INFERTILITY CASA MARKET BY GEOGRAPHY, 2012-2020 ($MILLION)
TABLE 8 GLOBAL MALE INFERTILITY SPERM AGGLUTINATION MARKET BY GEOGRAPHY, 2012-2020 ($MILLION)
TABLE 9 GLOBAL MALE INFERTILITY MICROSCOPIC EXAMINATION MARKET BY GEOGRAPHY, 2012-2020 ($MILLION)
TABLE 10 GLOBAL MALE INFERTILITY OTHERS MARKET BY GEOGRAPHY, 2012-2020 ($MILLION)
TABLE 11 NORTH AMERICAN MALE INFERTILITY MARKET, 2012-2020 ($MILLION)
TABLE 12 EUROPE MALE INFERTILITY MARKET, 2012-2020 ($MILLION)
TABLE 13 ASIA PACIFIC MALE INFERTILITY MARKET, 2012-2020 ($MILLION)
TABLE 14 ROW MALE INFERTILITY MARKET, 2012-2020 ($MILLION)
TABLE 15 EMD SERONO, INC BUSINESS SNAPSHOT
TABLE 16 ASKA PHARMACEUTICALS, INC BUSINESS SNAPSHOT
TABLE 17 ASKA PHARMACEUTICALS, INC BUSINESS SNAPSHOT
TABLE 18 ASKA PHARMACEUTICALS, INC BUSINESS SNAPSHOT
TABLE 19 PANTARHEI BIOSCIENCE B.V. BUSINESS SNAPSHOT
TABLE 20 CORDEX PHARMA, INC. BUSINESS SNAPSHOT
TABLE 21 HALOTECH DNA SL BUSINESS SNAPSHOT
TABLE 22 SCSA DIAGNOSTICS, INC. BUSINESS SNAPSHOT
TABLE 23 ANDROLOGY SOLUTIONS BUSINESS SNAPSHOT
TABLE 24 ACCESS PHARMACEUTICALS, INC. BUSINESS SNAPSHOT

LIST OF FIGURES
FIG. 1 TYPES OF MALE DISORDERS
FIG. 2 CONVENTIONAL, CURRENT AND ADVANCED TREATMENTS FOR MALE INFERTILITY
FIG. 3 PERCENTAGE OF RETRIEVALS WHICH RESULTED IN LIVE BIRTHS AMONG COUPLES WITH DIAGNOSED MALE FACTOR INFERTILITY USING IVF WITH ICSI (2010)
FIG. 4 MARKET SHARE OF MALE AND FEMALE INFERTILITY TREATMENT 2013 AND 2020
FIG. 5 MARKET SHARE OF MALE VERSUS FEMALE INFERTILITY TREATMENT MARKET (PERCENTAGE SHARE – 2013 TO 2020)
FIG. 6 MARKET SIZE FOR MALE INFERTILITY TREATMENTS MARKET, 2013 - 2020 ($MILLION)
FIG. 7 LEVEL OF FRAGMENTED DNA
FIG. 8 NUMBER OF DELIVERIES WITH OR WITHOUT MEASURING FRAGMENTATION
FIG. 9 SALES BY REGION, 2012
FIG. 10 HALOTECH DNA SL REVENUE BY YEAR (2012 – 2013)
FIG. 11 SCSA DIAGNOSTICS, INC. REVENUE BY YEAR (2012 – 2013)
FIG. 12 ACCESS PHARMACEUTICALS, INC. REVENUE BY YEAR (2011 – 2012)

PURCHASE OPTIONS
 
 

How can we help you?

Contact us at the Consulting WP office nearest to you or submit a business inquiry online.


  Contact
 

Subscribe to Our Newsletter

 
 
REQUEST SAMPLE    ASK FOR DISCOUNT